FDA Submission Guide

FDA Submission Guide

Complete framework for 510(k), De Novo, and PMA submissions to the FDA.

Table of Contents

• Submission Pathway Selection
• 510(k) Premarket Notification
• De Novo Classification
• PMA Premarket Approval
• Pre-Submission Program
• FDA Review Timeline

Submission Pathway Selection

Decision Matrix

Is there a legally marketed predicate device?
├── YES → Is your device substantially equivalent?
│   ├── YES → 510(k) Pathway
│   │   ├── No changes from predicate → Abbreviated 510(k)
│   │   ├── Manufacturing changes only → Special 510(k)
│   │   └── Design/performance changes → Traditional 510(k)
│   └── NO → PMA or De Novo
└── NO → Is it a novel low-to-moderate risk device?
    ├── YES → De Novo Classification Request
    └── NO → PMA Pathway (Class III)

Classification Determination

Predicate Device Search

Database Sources:

1. FDA 510(k) Database: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
2. FDA Product Classification Database
3. FDA PMA Database
4. FDA De Novo Database

Search Criteria:

• Product code (3-letter code)
• Device name keywords
• Intended use similarity
• Technological characteristics

510(k) Premarket Notification

Required Sections (21 CFR 807.87)

1. Administrative Information

Cover Letter
├── Submission type (Traditional/Special/Abbreviated)
├── Device name and classification
├── Predicate device(s) identification
├── Contact information
└── Signature of authorized representative

CDRH Premarket Review Submission Cover Sheet (FDA Form 3514)
├── Section A: Applicant Information
├── Section B: Device Information
├── Section C: Submission Information
└── Section D: Truth and Accuracy Statement

2. Device Description

3. Substantial Equivalence Comparison

Comparison Table Format:
┌────────────────────┬─────────────────┬─────────────────┐
│ Characteristic     │ Subject Device  │ Predicate       │
├────────────────────┼─────────────────┼─────────────────┤
│ Intended Use       │ [Your device]   │ [Predicate]     │
│ Technological      │                 │                 │
│ Characteristics    │                 │                 │
│ Performance        │                 │                 │
│ Safety             │                 │                 │
└────────────────────┴─────────────────┴─────────────────┘

Substantial Equivalence Argument:
1. Same intended use? YES/NO
2. Same technological characteristics? YES/NO
3. If different technology, does it raise new safety/effectiveness questions? YES/NO
4. Performance data demonstrates equivalence? YES/NO

4. Performance Testing

Bench Testing:

• Mechanical/structural testing
• Electrical safety (IEC 60601-1 if applicable)
• Biocompatibility (ISO 10993 series)
• Sterilization validation
• Shelf life/stability testing
• Software verification (IEC 62304 if applicable)

Clinical Data (if required):

• Clinical study summaries
• Literature review
• Adverse event data

5. Labeling

Required Elements:

• Instructions for Use (IFU)
• Device labeling (package, carton)
• Indications for Use statement
• Contraindications, warnings, precautions
• Advertising materials (if applicable)

510(k) Acceptance Checklist

## Pre-Submission Verification

- [ ] FDA Form 3514 complete and signed
- [ ] User fee payment ($21,760 for FY2024, small business exemptions available)
- [ ] Device description complete
- [ ] Predicate device identified with 510(k) number
- [ ] Substantial equivalence comparison table
- [ ] Indications for Use statement (FDA Form 3881)
- [ ] Performance data summary
- [ ] Labeling (IFU, device labels)
- [ ] 510(k) summary or statement
- [ ] Truthful and Accuracy statement signed
- [ ] Environmental assessment or categorical exclusion

De Novo Classification

Eligibility Criteria

1. Novel device with no legally marketed predicate
2. Low-to-moderate risk (would be Class I or II if predicate existed)
3. General controls alone (Class I) or with special controls (Class II) provide reasonable assurance of safety and effectiveness

Required Content

Risk Assessment

Risk Analysis Requirements:
├── Hazard Identification
│   ├── Biological hazards
│   ├── Mechanical hazards
│   ├── Electrical hazards
│   ├── Use-related hazards
│   └── Cybersecurity hazards (if applicable)
├── Risk Estimation
│   ├── Probability of occurrence
│   ├── Severity of harm
│   └── Risk level (High/Medium/Low)
├── Risk Evaluation
│   ├── Acceptability criteria
│   └── Benefit-risk analysis
└── Risk Control Measures
    ├── Design controls
    ├── Protective measures
    └── Information for safety

Proposed Classification

Special Controls (for Class II)

Define specific controls such as:

• Performance testing requirements
• Labeling requirements
• Post-market surveillance
• Patient registry
• Design specifications

PMA Premarket Approval

PMA Application Contents

Technical Sections

1. Device Description and Intended Use

   • Detailed design specifications
   • Operating principles
   • Complete indications for use

2. Manufacturing Information

   • Manufacturing process description
   • Quality system information
   • Facility registration

3. Nonclinical Laboratory Studies

   • Bench testing results
   • Animal studies (if applicable)
   • Biocompatibility testing

4. Clinical Investigation

   • IDE number and approval date
   • Clinical protocol
   • Clinical study results
   • Statistical analysis
   • Adverse events

5. Labeling

   • Complete labeling
   • Patient labeling (if applicable)

Clinical Data Requirements

Clinical Study Design:
├── Study Objectives
│   ├── Primary endpoint(s)
│   └── Secondary endpoint(s)
├── Study Population
│   ├── Inclusion criteria
│   ├── Exclusion criteria
│   └── Sample size justification
├── Study Design
│   ├── Randomized controlled trial
│   ├── Single-arm study with OPC
│   └── Other design with justification
├── Statistical Analysis Plan
│   ├── Analysis populations
│   ├── Statistical methods
│   └── Handling of missing data
└── Safety Monitoring
    ├── Adverse event definitions
    ├── Stopping rules
    └── DSMB oversight

IDE (Investigational Device Exemption)

When Required:

• Significant risk device clinical studies
• Studies not exempt under 21 CFR 812.2

IDE Application Content:

• Investigational plan
• Manufacturing information
• Investigator agreements
• IRB approvals
• Informed consent forms
• Labeling
• Risk analysis

Pre-Submission Program

Q-Submission Types

Pre-Sub Meeting Preparation

Pre-Submission Package:
1. Cover letter with meeting request
2. Device description
3. Regulatory history (if any)
4. Proposed submission pathway
5. Specific questions (maximum 5-6)
6. Supporting data/information

Meeting Types:
- Written response only (default)
- Teleconference (90 minutes)
- In-person meeting (90 minutes)

Effective Question Formulation

Good Question Format:

Question: Does FDA agree that [specific proposal] is acceptable for [specific purpose]?

Background: [Brief context - 1-2 paragraphs]

Proposal: [Your specific proposal - detailed but concise]

Rationale: [Why you believe this is appropriate]

Avoid:

• Open-ended questions ("What should we do?")
• Multiple questions combined
• Questions already answered in guidance

FDA Review Timeline

Standard Review Times

Review Process Stages

510(k) Review Timeline:
Day 0: Submission received
Day 1-15: Acceptance review
├── Accept → Substantive review begins
└── Refuse to Accept (RTA) → 180 days to respond

Day 15-90: Substantive review
├── Additional Information (AI) request stops clock
├── Interactive review may occur
└── Decision by Day 90 goal

Decision:
├── Substantially Equivalent (SE) → Clearance letter
├── Not Substantially Equivalent (NSE) → Appeal or new submission
└── Withdrawn

Additional Information Requests

Response Best Practices:

• Respond within 30-60 days
• Use FDA's question numbering
• Provide complete responses
• Include amended sections clearly marked
• Reference specific guidance documents

Submission Best Practices

Document Formatting

• Use PDF format (PDF/A preferred)
• Bookmarks for each section
• Hyperlinks to cross-references
• Table of contents with page numbers
• Consistent headers/footers

eSTAR (Electronic Submission Template)

FDA's recommended electronic submission format for 510(k):

• Structured data entry
• Built-in validation
• Automatic formatting
• Reduced RTA rate

Common Refuse to Accept (RTA) Issues